ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Paediatric Influenza Prevention Market Research Report 2026
Published Date: 2026-02-04
|
Report Code: QYRE-Auto-21M18486
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Paediatric Influenza Prevention Market Research Report 2024
BUY CHAPTERS

Global Paediatric Influenza Prevention Market Research Report 2026

Code: QYRE-Auto-21M18486
Report
2026-02-04
Pages:120
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
CSL Limited
GSK
Viatris
Hulan Bio
Astrazeneca plc
CCBIO
Sinovac
BCHT
Jiangsu GDK
KM Biologics

Paediatric Influenza Prevention Market Size

The global Paediatric Influenza Prevention market was valued at US$ 1781 million in 2025 and is anticipated to reach US$ 2319 million by 2032, at a CAGR of 3.9% from 2026 to 2032.

Paediatric Influenza Prevention Market

Paediatric Influenza Prevention Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Paediatric Influenza Prevention competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Pediatric influenza prevention focuses on strategies to protect children from the flu. This includes annual flu vaccination, which is highly recommended for children over six months old, as well as practices like regular handwashing, covering coughs, and avoiding close contact with infected individuals. Because young children are more vulnerable to severe flu complications, preventive measures are essential in minimizing their risk of infection and helping to prevent flu spread within families and communities.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report delivers a comprehensive overview of the global Paediatric Influenza Prevention market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Paediatric Influenza Prevention. The Paediatric Influenza Prevention market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Paediatric Influenza Prevention market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Paediatric Influenza Prevention manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Paediatric Influenza Prevention Market Report

Report Metric Details
Report Name Paediatric Influenza Prevention Market
Accounted market size in 2025 US$ 1781 million
Forecasted market size in 2032 US$ 2319 million
CAGR 3.9%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Nasal Spray
  • Injection
by Application
  • Public
  • Private
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, CSL, GSK, Viatris, Hulan Bio, AstraZeneca, CCBIO, Sinovac, BCHT, Jiangsu GDK, KM Biologics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Paediatric Influenza Prevention manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Paediatric Influenza Prevention sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Paediatric Influenza Prevention Market growing?

Ans: The Paediatric Influenza Prevention Market witnessing a CAGR of 3.9% during the forecast period 2026-2032.

What is the Paediatric Influenza Prevention Market size in 2032?

Ans: The Paediatric Influenza Prevention Market size in 2032 will be US$ 2319 million.

Who are the main players in the Paediatric Influenza Prevention Market report?

Ans: The main players in the Paediatric Influenza Prevention Market are Sanofi, CSL, GSK, Viatris, Hulan Bio, AstraZeneca, CCBIO, Sinovac, BCHT, Jiangsu GDK, KM Biologics

What are the Application segmentation covered in the Paediatric Influenza Prevention Market report?

Ans: The Applications covered in the Paediatric Influenza Prevention Market report are Public, Private

What are the Type segmentation covered in the Paediatric Influenza Prevention Market report?

Ans: The Types covered in the Paediatric Influenza Prevention Market report are Nasal Spray, Injection

1 Paediatric Influenza Prevention Market Overview
1.1 Product Definition
1.2 Paediatric Influenza Prevention by Type
1.2.1 Global Paediatric Influenza Prevention Market Value by Type: 2025 vs 2032
1.2.2 Nasal Spray
1.2.3 Injection
1.3 Paediatric Influenza Prevention by Application
1.3.1 Global Paediatric Influenza Prevention Market Value by Application: 2025 vs 2032
1.3.2 Public
1.3.3 Private
1.4 Global Paediatric Influenza Prevention Market Size Estimates and Forecasts
1.4.1 Global Paediatric Influenza Prevention Revenue 2021–2032
1.4.2 Global Paediatric Influenza Prevention Sales 2021–2032
1.4.3 Global Paediatric Influenza Prevention Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Paediatric Influenza Prevention Market Competition by Manufacturers
2.1 Global Paediatric Influenza Prevention Sales Market Share by Manufacturers (2021–2026)
2.2 Global Paediatric Influenza Prevention Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Paediatric Influenza Prevention Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Paediatric Influenza Prevention, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Paediatric Influenza Prevention, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Paediatric Influenza Prevention, Product Types and Applications
2.7 Global Key Manufacturers of Paediatric Influenza Prevention, Date of Entry into the Industry
2.8 Global Paediatric Influenza Prevention Market Competitive Situation and Trends
2.8.1 Global Paediatric Influenza Prevention Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Paediatric Influenza Prevention Players Market Share by Revenue
2.8.3 Global Paediatric Influenza Prevention Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Paediatric Influenza Prevention Market Scenario by Region
3.1 Global Paediatric Influenza Prevention Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Paediatric Influenza Prevention Sales by Region: 2021–2032
3.2.1 Global Paediatric Influenza Prevention Sales by Region: 2021–2026
3.2.2 Global Paediatric Influenza Prevention Sales by Region: 2027–2032
3.3 Global Paediatric Influenza Prevention Revenue by Region: 2021–2032
3.3.1 Global Paediatric Influenza Prevention Revenue by Region: 2021–2026
3.3.2 Global Paediatric Influenza Prevention Revenue by Region: 2027–2032
3.4 North America Paediatric Influenza Prevention Market Facts & Figures by Country
3.4.1 North America Paediatric Influenza Prevention Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Paediatric Influenza Prevention Sales by Country (2021–2032)
3.4.3 North America Paediatric Influenza Prevention Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paediatric Influenza Prevention Market Facts & Figures by Country
3.5.1 Europe Paediatric Influenza Prevention Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Paediatric Influenza Prevention Sales by Country (2021–2032)
3.5.3 Europe Paediatric Influenza Prevention Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paediatric Influenza Prevention Market Facts & Figures by Region
3.6.1 Asia Pacific Paediatric Influenza Prevention Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Paediatric Influenza Prevention Sales by Region (2021–2032)
3.6.3 Asia Pacific Paediatric Influenza Prevention Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Paediatric Influenza Prevention Market Facts & Figures by Country
3.7.1 Latin America Paediatric Influenza Prevention Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Paediatric Influenza Prevention Sales by Country (2021–2032)
3.7.3 Latin America Paediatric Influenza Prevention Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Paediatric Influenza Prevention Market Facts & Figures by Country
3.8.1 Middle East and Africa Paediatric Influenza Prevention Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Paediatric Influenza Prevention Sales by Country (2021–2032)
3.8.3 Middle East and Africa Paediatric Influenza Prevention Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paediatric Influenza Prevention Sales by Type (2021–2032)
4.1.1 Global Paediatric Influenza Prevention Sales by Type (2021–2026)
4.1.2 Global Paediatric Influenza Prevention Sales by Type (2027–2032)
4.1.3 Global Paediatric Influenza Prevention Sales Market Share by Type (2021–2032)
4.2 Global Paediatric Influenza Prevention Revenue by Type (2021–2032)
4.2.1 Global Paediatric Influenza Prevention Revenue by Type (2021–2026)
4.2.2 Global Paediatric Influenza Prevention Revenue by Type (2027–2032)
4.2.3 Global Paediatric Influenza Prevention Revenue Market Share by Type (2021–2032)
4.3 Global Paediatric Influenza Prevention Price by Type (2021–2032)
5 Segment by Application
5.1 Global Paediatric Influenza Prevention Sales by Application (2021–2032)
5.1.1 Global Paediatric Influenza Prevention Sales by Application (2021–2026)
5.1.2 Global Paediatric Influenza Prevention Sales by Application (2027–2032)
5.1.3 Global Paediatric Influenza Prevention Sales Market Share by Application (2021–2032)
5.2 Global Paediatric Influenza Prevention Revenue by Application (2021–2032)
5.2.1 Global Paediatric Influenza Prevention Revenue by Application (2021–2026)
5.2.2 Global Paediatric Influenza Prevention Revenue by Application (2027–2032)
5.2.3 Global Paediatric Influenza Prevention Revenue Market Share by Application (2021–2032)
5.3 Global Paediatric Influenza Prevention Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi Paediatric Influenza Prevention Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 CSL
6.2.1 CSL Company Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 CSL Paediatric Influenza Prevention Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GSK Paediatric Influenza Prevention Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Company Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Viatris Paediatric Influenza Prevention Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 Hulan Bio
6.5.1 Hulan Bio Company Information
6.5.2 Hulan Bio Description and Business Overview
6.5.3 Hulan Bio Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Hulan Bio Paediatric Influenza Prevention Product Portfolio
6.5.5 Hulan Bio Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Paediatric Influenza Prevention Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 CCBIO
6.7.1 CCBIO Company Information
6.7.2 CCBIO Description and Business Overview
6.7.3 CCBIO Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 CCBIO Paediatric Influenza Prevention Product Portfolio
6.7.5 CCBIO Recent Developments/Updates
6.8 Sinovac
6.8.1 Sinovac Company Information
6.8.2 Sinovac Description and Business Overview
6.8.3 Sinovac Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Sinovac Paediatric Influenza Prevention Product Portfolio
6.8.5 Sinovac Recent Developments/Updates
6.9 BCHT
6.9.1 BCHT Company Information
6.9.2 BCHT Description and Business Overview
6.9.3 BCHT Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 BCHT Paediatric Influenza Prevention Product Portfolio
6.9.5 BCHT Recent Developments/Updates
6.10 Jiangsu GDK
6.10.1 Jiangsu GDK Company Information
6.10.2 Jiangsu GDK Description and Business Overview
6.10.3 Jiangsu GDK Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Jiangsu GDK Paediatric Influenza Prevention Product Portfolio
6.10.5 Jiangsu GDK Recent Developments/Updates
6.11 KM Biologics
6.11.1 KM Biologics Company Information
6.11.2 KM Biologics Description and Business Overview
6.11.3 KM Biologics Paediatric Influenza Prevention Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 KM Biologics Paediatric Influenza Prevention Product Portfolio
6.11.5 KM Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paediatric Influenza Prevention Industry Chain Analysis
7.2 Paediatric Influenza Prevention Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paediatric Influenza Prevention Production Mode & Process Analysis
7.4 Paediatric Influenza Prevention Sales and Marketing
7.4.1 Paediatric Influenza Prevention Sales Channels
7.4.2 Paediatric Influenza Prevention Distributors
7.5 Paediatric Influenza Prevention Customer Analysis
8 Paediatric Influenza Prevention Market Dynamics
8.1 Paediatric Influenza Prevention Industry Trends
8.2 Paediatric Influenza Prevention Market Drivers
8.3 Paediatric Influenza Prevention Market Challenges
8.4 Paediatric Influenza Prevention Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sanofi
CSL Limited
GSK
Viatris
Hulan Bio
Astrazeneca plc
CCBIO
Sinovac
BCHT
Jiangsu GDK
KM Biologics
List of Tables
 Table 1. Global Paediatric Influenza Prevention Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Paediatric Influenza Prevention Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Paediatric Influenza Prevention Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Paediatric Influenza Prevention Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Paediatric Influenza Prevention Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Paediatric Influenza Prevention Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Paediatric Influenza Prevention Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Paediatric Influenza Prevention Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Paediatric Influenza Prevention, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Paediatric Influenza Prevention, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Paediatric Influenza Prevention, Product Types and Applications
 Table 12. Global Key Manufacturers of Paediatric Influenza Prevention, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Paediatric Influenza Prevention Companies by Tier (Tier 1, Tier 2, Tier 3), based on Paediatric Influenza Prevention Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Paediatric Influenza Prevention Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Paediatric Influenza Prevention Sales by Region (K Units), 2021–2026
 Table 18. Global Paediatric Influenza Prevention Sales Market Share by Region (2021–2026)
 Table 19. Global Paediatric Influenza Prevention Sales by Region (K Units), 2027–2032
 Table 20. Global Paediatric Influenza Prevention Sales Market Share by Region (2027–2032)
 Table 21. Global Paediatric Influenza Prevention Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Paediatric Influenza Prevention Revenue Market Share by Region (2021–2026)
 Table 23. Global Paediatric Influenza Prevention Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Paediatric Influenza Prevention Revenue Market Share by Region (2027–2032)
 Table 25. North America Paediatric Influenza Prevention Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Paediatric Influenza Prevention Sales by Country (K Units), 2021–2026
 Table 27. North America Paediatric Influenza Prevention Sales by Country (K Units), 2027–2032
 Table 28. North America Paediatric Influenza Prevention Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Paediatric Influenza Prevention Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Paediatric Influenza Prevention Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Paediatric Influenza Prevention Sales by Country (K Units), 2021–2026
 Table 32. Europe Paediatric Influenza Prevention Sales by Country (K Units), 2027–2032
 Table 33. Europe Paediatric Influenza Prevention Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Paediatric Influenza Prevention Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Paediatric Influenza Prevention Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Paediatric Influenza Prevention Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Paediatric Influenza Prevention Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Paediatric Influenza Prevention Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Paediatric Influenza Prevention Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Paediatric Influenza Prevention Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Paediatric Influenza Prevention Sales by Country (K Units), 2021–2026
 Table 42. Latin America Paediatric Influenza Prevention Sales by Country (K Units), 2027–2032
 Table 43. Latin America Paediatric Influenza Prevention Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Paediatric Influenza Prevention Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Paediatric Influenza Prevention Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Paediatric Influenza Prevention Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Paediatric Influenza Prevention Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Paediatric Influenza Prevention Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Paediatric Influenza Prevention Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Paediatric Influenza Prevention Sales (K Units) by Type (2021–2026)
 Table 51. Global Paediatric Influenza Prevention Sales (K Units) by Type (2027–2032)
 Table 52. Global Paediatric Influenza Prevention Sales Market Share by Type (2021–2026)
 Table 53. Global Paediatric Influenza Prevention Sales Market Share by Type (2027–2032)
 Table 54. Global Paediatric Influenza Prevention Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Paediatric Influenza Prevention Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Paediatric Influenza Prevention Revenue Market Share by Type (2021–2026)
 Table 57. Global Paediatric Influenza Prevention Revenue Market Share by Type (2027–2032)
 Table 58. Global Paediatric Influenza Prevention Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Paediatric Influenza Prevention Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Paediatric Influenza Prevention Sales (K Units) by Application (2021–2026)
 Table 61. Global Paediatric Influenza Prevention Sales (K Units) by Application (2027–2032)
 Table 62. Global Paediatric Influenza Prevention Sales Market Share by Application (2021–2026)
 Table 63. Global Paediatric Influenza Prevention Sales Market Share by Application (2027–2032)
 Table 64. Global Paediatric Influenza Prevention Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Paediatric Influenza Prevention Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Paediatric Influenza Prevention Revenue Market Share by Application (2021–2026)
 Table 67. Global Paediatric Influenza Prevention Revenue Market Share by Application (2027–2032)
 Table 68. Global Paediatric Influenza Prevention Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Paediatric Influenza Prevention Price (US$/Unit) by Application (2027–2032)
 Table 70. Sanofi Company Information
 Table 71. Sanofi Description and Business Overview
 Table 72. Sanofi Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Sanofi Paediatric Influenza Prevention Product
 Table 74. Sanofi Recent Developments/Updates
 Table 75. CSL Company Information
 Table 76. CSL Description and Business Overview
 Table 77. CSL Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. CSL Paediatric Influenza Prevention Product
 Table 79. CSL Recent Developments/Updates
 Table 80. GSK Company Information
 Table 81. GSK Description and Business Overview
 Table 82. GSK Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. GSK Paediatric Influenza Prevention Product
 Table 84. GSK Recent Developments/Updates
 Table 85. Viatris Company Information
 Table 86. Viatris Description and Business Overview
 Table 87. Viatris Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Viatris Paediatric Influenza Prevention Product
 Table 89. Viatris Recent Developments/Updates
 Table 90. Hulan Bio Company Information
 Table 91. Hulan Bio Description and Business Overview
 Table 92. Hulan Bio Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Hulan Bio Paediatric Influenza Prevention Product
 Table 94. Hulan Bio Recent Developments/Updates
 Table 95. AstraZeneca Company Information
 Table 96. AstraZeneca Description and Business Overview
 Table 97. AstraZeneca Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. AstraZeneca Paediatric Influenza Prevention Product
 Table 99. AstraZeneca Recent Developments/Updates
 Table 100. CCBIO Company Information
 Table 101. CCBIO Description and Business Overview
 Table 102. CCBIO Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. CCBIO Paediatric Influenza Prevention Product
 Table 104. CCBIO Recent Developments/Updates
 Table 105. Sinovac Company Information
 Table 106. Sinovac Description and Business Overview
 Table 107. Sinovac Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Sinovac Paediatric Influenza Prevention Product
 Table 109. Sinovac Recent Developments/Updates
 Table 110. BCHT Company Information
 Table 111. BCHT Description and Business Overview
 Table 112. BCHT Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. BCHT Paediatric Influenza Prevention Product
 Table 114. BCHT Recent Developments/Updates
 Table 115. Jiangsu GDK Company Information
 Table 116. Jiangsu GDK Description and Business Overview
 Table 117. Jiangsu GDK Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Jiangsu GDK Paediatric Influenza Prevention Product
 Table 119. Jiangsu GDK Recent Developments/Updates
 Table 120. KM Biologics Company Information
 Table 121. KM Biologics Description and Business Overview
 Table 122. KM Biologics Paediatric Influenza Prevention Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. KM Biologics Paediatric Influenza Prevention Product
 Table 124. KM Biologics Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Paediatric Influenza Prevention Distributors List
 Table 128. Paediatric Influenza Prevention Customers List
 Table 129. Paediatric Influenza Prevention Market Trends
 Table 130. Paediatric Influenza Prevention Market Drivers
 Table 131. Paediatric Influenza Prevention Market Challenges
 Table 132. Paediatric Influenza Prevention Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Paediatric Influenza Prevention
 Figure 2. Global Paediatric Influenza Prevention Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Paediatric Influenza Prevention Market Share by Type: 2025 & 2032
 Figure 4. Nasal Spray Product Picture
 Figure 5. Injection Product Picture
 Figure 6. Global Paediatric Influenza Prevention Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Paediatric Influenza Prevention Market Share by Application: 2025 & 2032
 Figure 8. Public
 Figure 9. Private
 Figure 10. Global Paediatric Influenza Prevention Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 11. Global Paediatric Influenza Prevention Market Size (US$ Million), 2021–2032
 Figure 12. Global Paediatric Influenza Prevention Sales (K Units), 2021–2032
 Figure 13. Global Paediatric Influenza Prevention Average Price (US$/Unit), 2021–2032
 Figure 14. Paediatric Influenza Prevention Report Years Considered
 Figure 15. Paediatric Influenza Prevention Sales Share by Manufacturers in 2025
 Figure 16. Global Paediatric Influenza Prevention Revenue Share by Manufacturers in 2025
 Figure 17. Top 5 and Top 10 Global Paediatric Influenza Prevention Players: Market Share by Revenue in Paediatric Influenza Prevention in 2025
 Figure 18. Paediatric Influenza Prevention Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 19. Global Paediatric Influenza Prevention Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 20. North America Paediatric Influenza Prevention Sales Market Share by Country (2021–2032)
 Figure 21. North America Paediatric Influenza Prevention Revenue Market Share by Country (2021–2032)
 Figure 22. United States Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 23. Canada Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Europe Paediatric Influenza Prevention Sales Market Share by Country (2021–2032)
 Figure 25. Europe Paediatric Influenza Prevention Revenue Market Share by Country (2021–2032)
 Figure 26. Germany Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. France Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. U.K. Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Italy Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Russia Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Asia Pacific Paediatric Influenza Prevention Sales Market Share by Region (2021–2032)
 Figure 32. Asia Pacific Paediatric Influenza Prevention Revenue Market Share by Region (2021–2032)
 Figure 33. China Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Japan Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. South Korea Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. India Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Australia Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. China Taiwan Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Indonesia Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Thailand Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Malaysia Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America Paediatric Influenza Prevention Sales Market Share by Country (2021–2032)
 Figure 43. Latin America Paediatric Influenza Prevention Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Paediatric Influenza Prevention Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Paediatric Influenza Prevention Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Paediatric Influenza Prevention Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Paediatric Influenza Prevention by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Paediatric Influenza Prevention by Type (2021–2032)
 Figure 54. Global Paediatric Influenza Prevention Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Paediatric Influenza Prevention by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Paediatric Influenza Prevention by Application (2021–2032)
 Figure 57. Global Paediatric Influenza Prevention Price (US$/Unit) by Application (2021–2032)
 Figure 58. Paediatric Influenza Prevention Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Flu Prevention Market Research Report 2024
Global Paediatric Influenza Treatment Market Research Report 2024
Global Pediatric Influenza Treatment Market Insights Forecast to 2030
Children Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pediatric Preventable Vaccine Market Research Report 2024
Global Flu Vaccination Market Research Report 2025
Global Human Injection Flu Vaccine Market Research Report 2025
Global Injection Influenza Vaccine Market Research Report 2025
Global Flu Vaccine Market Insights Forecast to 2030
Global Injection Flu Shot Market Research Report 2025
Global Vaccines For Children Market Insights Forecast to 2030
Global Influenza Subunit Vaccine Market Research Report 2024
Global Flu RNA Vaccines Market Research Report 2025
Global Pediatric Anti Flu Drugs Market Insights Forecast to 2030
Global Pediatric Healthcare Service Market Research Report 2024
Global Pediatric Healthcare Market Research Report 2025
Global Pediatric Anti Infective Drugs Market Research Report 2025
Global Combination Vaccines for Children Market Research Report 2024
Global Adult and Pediatric Vaccines Market Research Report 2024
Global Paediatric Mask Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions